Health Dictionary Find a Doctor

Constipation

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Eiman Ghaffarpasand, M.D. [2]

Synonyms and keywords:Hard stool, Hard feces, Idiopathic constipation.

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

Constipation is defined as straining, hard stool, sensation of incomplete evacuation, sensation of obstruction, necessity of manual maneuvers, less than 3 bowel movements per week, lack of loose stool, and lack of irritable bowel syndrome (IBS). Constipation is classified according to etiology into seven subtypes including gastrointestinal, neurologic, metabolic, endocrine, psychiatric, drug-induced, and idiopathic The defecation process consist of three important stages, include filling of the rectum, sensation of rectum fullness, and relaxation of pelvic floor muscles in a coordinated fashion. Primary constipation is caused by anorectal and colonic problems, while secondary constipation is caused by organic and metabolic diseases or medications. Diseases that disturb the nervous system may lead to constipation, such as diabetes mellitus, autonomic neuropathy, Chagas’ disease, and Hirschsprung’s disease. Chronic use of the laxative may lead to melanosis coli, which is identified by hyperpigmentation and brownish discoloration of colonic mucosa. The primary histopathological finding in melanosis coli is brown granular pigment in lamina propria. Diagnostic study of choice for constipation is ROME III criteria. Rome III criteria includes symptom onset for more than 6 months and two or more number of specific symptoms. Specific constipation symptoms include straining, hard stool, sensation of incomplete evacuation, sensation of obstruction, necessity of manual maneuvers, less than 3 bowel movements per week, lack of loose stool, and lack of irritable bowel syndrome (IBS). Chronic constipation treatment includes both behavioral and pharmacological interventions. Behavioral management mostly consists of life style and dietary modification, while pharmacological interventions are mostly based on laxatives. Increasing physical activity is postulated to improve constipation and colonic transit time in patients with constipation. The most important behavioral treatment for constipation is biofeedback, consisting of teaching the patients how to use their abdominal and pelvic muscles during defecation. Probiotics are live microorganism spores that are given orally to improve the gastrointestinal tract function. Recently, using probiotics in food industry is growing. Bifidobacterium and Lactobacillus are most evaluated organisms as probiotics.

Historical Perspective

The Egyptian Ebers papyrus, from 16th century BC is the first book that presented a basic description for constipation. Ebers papyrus defined constipation as intoxication of body with hazardous agents from feces in bowels. In early 1900s, all-bran products were first introduced to prevent and treat auto-intoxicated patients due to constipation. In 1970s and 1980s, Denis Burkitt, an English surgeon, claimed the hypothesis about dietary fibers followed by the definition of “The Commonest Western disease”.

Classification

Constipation is classified according to etiology into seven subtypes include gastrointestinal, neurologic, metabolic, endocrine, psychiatric, drug-induced, and idiopathic.

Pathophysiology

About 1.5 liter fluid enters the colon from small intestine every day. Colon only excrete out 200-400 mL stool. The defecation process consist of three important stages, include filling of the rectum, sensation of rectum fullness, and relaxation of pelvic floor muscles in a coordinated fashion. Primary constipation is caused by anorectal and colonic problems, while secondary constipation is caused by organic and metabolic diseases or medications. Diseases that disturb the nervous system may lead to constipation, such as diabetes mellitus, autonomic neuropathy, Chagas’ disease, and Hirschsprung’s disease. Chronic use of the laxative may lead to melanosis coli, which is identified by hyperpigmentation and brownish discoloration of colonic mucosa. The primary histopathological finding in melanosis coli is brown granular pigment in lamina propria.

Causes

Constipation in adults may be due to side effects of medications, such as antispasmodics, anticholinergics, analgesics; or may be associated with systemic disorders, such as diabetes mellitus and hypothyroidism. Idiopathic constipation should be considered once the secondary causes are ruled out and it may be associated with normal or slow colonic transit, dysfunction in defecation, or both. Constipation in childhood often resolves with age after proper guidance regarding diet, toilet training, and toileting behaviors.

Differentiating Constipation overview from Other Diseases

Diseases that cause constipation should differentiate from each others, such as malignancy, diabetic autonomic neuropathy, irritable bowel syndrome, rectocele, fissure, anismus, systemic sclerosis, hypothyroidism, Parkinson’s disease, multiple sclerosis, hypomagnesemia, hypocalcemia, and depression.

Epidemiology and Demographics

The incidence of constipation is approximately 16,666 per 100,000 individuals in general population (one in every six). The prevalence of constipation is approximately 2,000 to 28,000 per 100,000 individuals in general population. It is estimated that 4-56 million people are suffering from constipation in United States. The prevalence of constipation is approximately 1,900 to 27,200 (with an average of 14,800) per 100,000 individuals in North America. The general decline in 10-year survival rate of people with functional constipation is about 12%, comparing to normal population. The incidence of constipation increases with age. The non-White to White ratio of involving in constipation is from 1.13 to 2.89 (Mean 1.68, Median 1.41). Females are more commonly affected by constipation than males. The female to male ratio is approximately 2.2 to 1. Developing countries with lower income show higher prevalence of constipation rather than developed countries with higher income. Educational years in the population show an inverse relationship with prevalence of constipation.

Risk Factors

The most potent risk factor in the development of constipation is inappropriate diet. Common risk factors include female gender, > 65 years of age, pregnancy, and Iron supplements.

Screening

According to the USPSTF, screening for constipation is not recommended in general population. In palliative care patients, screening for constipation by specific questionnaire about subjective and objective findings is recommended.

Natural History, Complications, and Prognosis

The symptoms of constipation can develop in the different decades of life, and starts with symptoms such as bloating, mucus passage, and abdominal pain. Then the symptoms increase in severity by hardening of stool which is contributes to straining and inability to pass the stool, may be need for manual evacuation. Common complications of chronic constipation include hemorrhoid, anal fissure, fecal impaction, and rectal prolapse. The colonic transit time (CTT) more than 100 hours is associated with a particularly poor prognosis among patients with constipation.

Diagnosis

Diagnostic study of choice

Diagnostic study of choice for constipation is ROME III criteria. Rome III criteria includes symptom onset for more than 6 months and two or more number of specific symptoms. Specific symptoms of constipation include straining, hard stool, sensation of incomplete evacuation, sensation of obstruction, necessity of manual maneuvers, less than 3 bowel movements per week, lack of loose stool, and lack of irritable bowel syndrome (IBS).

History and Symptoms

A positive history of straining, hard stools, sensation of incomplete evacuation, sensation of anorectal obstruction, use of manual maneuvers, and less than 3 defecations weekly is suggestive of constipation. The most common symptoms of constipation include infrequent bowel movements, abdominal bloating, necessity to strain, and anal pain. Less common symptoms of constipation include abdominal fullness, visible abdominal distention, incomplete evacuation, abdominal pain, rectal bleeding, and mass protrusion. Bristol Stool Form Scale and Patient Assessment Constipation-Quality of Life (PAC-QOL) are two questionnaire based on patients symptoms, help to diagnose constipation and quality of life in constipated patients.

Physical Examination

Physical examination of patients with constipation is usually remarkable for anal fissure or palpable lumpy mass in abdomen (particularly in left quadrant). The presence of thrombosed external hemorrhoids, skin tags, rectal prolapse, anal fissure, anal warts, excoriation or evidence of pruritus ani due to fecal soiling on physical examination are suggestive of constipation. Patients with chronic constipation usually appear to be discomfort while sitting due to anal pain.

Laboratory Findings

There are no diagnostic laboratory findings necessary for diagnosing constipation in young people without alarm signs. Laboratory test for exclusion of underlying diseases are complete blood count, blood urea nitrogen (BUN)/creatinine, serum phosphate levels, blood glucose levels, liver function tests (LFTs), fecal occult blood test, thyroid function tests, serum calcium levels, and serum magnesium levels. In case of high suspicion, other laboratory tests may be needed such as serum protein electrophoresis, urine porphyrins, serum parathyroid hormone, and serum cortisol levels.

Abdominal X Ray

An abdominal X-ray may be helpful in the diagnosis of constipation. Findings on an X-ray suggestive of constipation is interpreted according to three scoring system, including Barr, Blethyn, and Leech systems. Barr scoring system is the first scoring method used to interpret abdominal X-ray suggestive of constipation. The total score of more than 10 was postulated as diagnosis of constipation. The revised scoring system of Blethyn (a simplified version of Barr scoring system) is based on the amount of remained feces in large bowel. The Blethyn scoring system consists of 4 grades of fecal retention in bowels. The most studies and organized scoring system for diagnosis of constipation is Leech method. The score of more than 8 is considered as constipation.

CT

There are no CT scan findings associated with constipation.

MRI

Different MRI modalities may be helpful in the diagnosis of constipation underlying diseases. Four types of MRI which are used for diagnosing constipation are conventional pelvic MRI, dynamic MRI (MR defecography), endoanal MRI, and fluoroscopic MRI. Pelvic MRI mostly reveals the general structure and anatomy of pelvic organs. Findings on MR defecography suggestive of constipation include various types of rectal prolapse (mucosal or full-thickness), disorders of pelvic floor muscles movements, very acute anorectal angle, and Increased perineal descent degree during rectal evacuation. The major findings on endoanal MRI are thinning of sphincter muscles, disruption of sphincter muscles, and changes in the anorectal angle. MRI fluoroscopy is a real time modality that evaluates the pelvic floor and viscera during defecation, valsalva maneuver, and evacuation process.

Ultrasound

Endoanal ultrasound may be helpful for diagnosing underlying diseases causing constipation, particularly sphincter pathologies. Findings on an ultrasound suggestive of sphincter disorders are decline in thickness, depth, and size of the sphincter muscle. Endoanal ultrasound findings are scored through Starck scoring system, based on thickness, depth, and size of the sphincter muscles. The sphincter abnormality is classified as small (score of 1-4), moderate (score of 5-7), or large (score of 8-16).

Other imaging findings

Barium enema may be helpful in diagnosing underlying diseases of constipation. Findings on a barium enema suggestive of constipation are redundant sigmoid colon, megacolon, megarectum, extrinsic compression, and intraluminal masses. Defecography may be helpful in diagnosing underlying diseases causing constipation. Findings on a defecography suggestive of constipation are poor activation of levator ani muscle, prolonged retention or inability to expel the barium, absence of a stripping wave in the rectum, mucosal intussusceptions, or rectocele. The transit time of the colon can be measured by means of various methods, include radiopaque marker ingestion, radioisotope and scintigraphy study, and wireless motility capsule.

Other diagnostic studies

Endoscopic evaluation of patients with constipation include flexible sigmoidoscopy and colonoscopy. Flexible sigmoidoscopy is the direct visualization of the rectum and sigmoid colon. However, colonoscopy is study of the whole colon lumen. Every patient with alarm signs have to be evaluated using colonoscopy. In younger patients, flexible sigmoidoscopy would be sufficient for further investigation of alarm signs. Colonic manometry is 24-hour measurement of pressure within the large bowel, using specific probes and portable recorders. Anorectal manometry is studying the pressure activity of anorectum during rest and defecation, along with rectal sensation, rectoanal reflexes, and anal sphincter function. Balloon expulsion test is a simple bedside test to evaluate the ability of patient to evacuate the artificial stool. Rectal biostat test consists of a very compliant plastic balloon, which is inserted into the rectum, concurrently connected to computer device to measure the pressure.

Treatment

Medical Therapy

Chronic constipation treatment includes both behavioral and pharmacological interventions. Behavioral management mostly consists of life style and dietary modification, while pharmacological interventions are mostly based on laxatives. Increasing physical activity is postulated to improve constipation and colonic transit time in patients with constipation. The most important behavioral treatment for constipation is biofeedback, consisting of teaching the patients how to use their abdominal and pelvic muscles during defecation. Probiotics are live microorganisms that are eaten to improve the gastrointestinal tract function. Recently, use of probiotics in food industry is growing. Bifidobacterium and Lactobacillus are most studied organisms as probiotics.

Surgery

Surgery is not the first-line treatment option for patients with constipation. Surgery is usually reserved for patients with either rectopexy, total colectomy, and subtotal colectomy with ileorectal anastomosis. 

Primary Prevention

Constipation is usually easier to prevent than to treat. The relief of constipation with osmotic agents, i.e., lactulose, polyethylene glycol (PEG), or magnesium salts, should also be immediately followed by prevention using increased fiber (fruits, vegetables, and grains) and a nightly decreasing dose of osmotic laxative. Effective measures for the primary prevention of constipation include fiber supplementation, appropriate fluid intake, toilet habits, and exercise.

Secondary Prevention

Effective measures for the secondary prevention of constipation include appropriate dietary modification and addition of fiber, suitable laxative and stool softener therapies, and avoiding harmful food products while constipated.

References

Template:WikiDoc Sources

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

The Egyptian Ebers papyrus, from 16th century BC is the first book that presented a basic description for constipation. Ebers papyrus defined constipation as intoxication of body with hazardous agents from feces in bowels. In early 1900s, all-bran products were first introduced to prevent and treat auto-intoxicated patients due to constipation. In 1970s and 1980s, Denis Burkitt, an English surgeon, claimed the hypothesis about dietary fibers followed by the definition of “The Commonest Western disease”.

Historical Perspective

 
 
 
 
 
 
16th century BC
The Egyptian Ebers papyrus
First definition of constipation as intoxication of body toxins from feces in bowels
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18th century
Personal physician of Louis XV in France
Defined constipation as blood pollution by toxins released from remaining wastes in the intestines
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beginning of 19th century
Physicians
Believed constipation as a disease of civilization and urban population
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1850s
An American health manual
Revealed that “daily emptying the bowels is of the utmost importance in being healthy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease perspective
 
 
1906
Charles Bouchard, a French physician
Proposed the “auto-intoxication theory
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1923
William Walsh, an American physician
Mentioned that not all the symptoms are related to poisons released from feces remaining in bowel
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1924
Arbuthnot Lane, a British physician
Pointed out “the whiter your bread, the sooner you’re dead
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1928
Charles Campbell, an American physician
Postulated that wastes remaining in colon are decomposing and may make the body full of poisons
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1928
Victor Paucher, a French internist
Suggested that stasis of feces in bowels creates “Sewer-like blood”
 
 
 


  • The Egyptian Ebers papyrus, from 16th century BC, is the first book that presented a basic description for constipation. Ebers papyrus defined constipation as intoxication of body with hazardous agents from feces in bowels.[1]
  • In 18th century, the personal physician of Louis XV in France, presented a similar definition as Ebers papyrus. He mentioned the constipation as blood pollution with released toxins from remained wastes in the intestines.[2]
  • In the beginning of 19th century, physicians believed that constipation was a disease of civilization and urban population was mostly involved with constipation.[3]
  • In 1850s, an American health manual revealed that “daily emptying the bowels is of the utmost importance in being healthy“. Daily bowel movement was also suggested to prevent derangement and disturbance in body.[4]
  • In 1906, Charles Bouchard, a French physician proposed the “auto-intoxication theory“, constipated person is continuously trying to commit suicide by auto-intoxication with toxins which are produced by feces remaining in his intestine.[5]
  • In 1923, William Walsh, an American physician, mentioned that not all the symptoms and severity of constipation are related to poisons released from feces remaining in bowels.[6]
  • In 1924, Arbuthnot Lane, a British physician, pointed out the relation between colon cancer and constipation. Lane presented that “the whiter your bread, the sooner you’re dead”.[7]
  • In 1928, Charles Campbell, an American physician, postulated that wastes remaining in colon are decomposing and may make the body full of poisons.[8]
  • In 1928, Victor Paucher, a French internist, suggested that stasis of feces in bowels make poisons secreted into blood and creates “Sewer-like blood”.[9]

Landmark Events in the Development of Treatment Strategies

 
 
 
 
1900
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All-bran products were first introduced for the prevention and treatment of auto-intoxication due to constipation
 
 
 
 
 
 
 
 
 
 
 
Early 1900s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yeasts introduced in the yogurt were also postulated to prevent the constipation and following auto-intoxication
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arbuthnot Lane, a British physician, introduced Phenolphthalein as a strong laxative for children
 
 
 
 
 
 
 
 
 
 
 
1913
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arbuthnot Lane also revealed that maintaining the normal human “drainage scheme” is the primary treatment for constipation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1981
 
Denis Burkitt an English surgeon, claimed the hypothesis about dietary fibers followed by the definition of “The Commonest Western disease”
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2000
 
 


  • In early 1900s, all-bran products were first introduced for the prevention and treatment of auto-Intoxication due to constipation.[3]
  • In early 1900s, yeasts were also postulated to prevent the constipation and the auto-intoxication that follows, when introduced in the yogurt.[3]
  • In 1913, Phenolphthalein was introduced as a strong laxative for children. Phenolphthalein quickly became the best laxative.[7]
  • From 1900 to 1920, Arbuthnot Lane, a British physician, revealed that maintaining the normal human “drainage scheme” is the primary treatment for constipation.[7]
  • In 1970s and 1980s, Denis Burkitt an English surgeon, claimed the hypothesis about dietary fibers followed by the definition of “The Commonest Western disease”.[10]

References

  1. Ebbell, B. (Bendix), 1865- (1937), The Papyrus Ebers : the greatest Egyptian medical document, Levin & Munksgaard, retrieved 14 November 2017
  2. Lieutaud, Joseph, 1703-1780; Atlee, Edwin Augustus, 1776-1852 (1816), Synopsis of the universal practice of medicine [electronic resource] : exhibiting a concise view of all diseases, both internal and external : illustrated with complete commentaries / by Joseph Lieutaud ; translated from the Latin by Edwin A. Atlee, Edward and Richard Parker
  3. 3.0 3.1 3.2 Whorton J (2000). “Civilisation and the colon: constipation as the “disease of diseases. BMJ. 321 (7276): 1586–9. PMC 1119264. PMID 11124189.
  4. Root, Harmon Knox (1854), People’s medical lighthouse; a series of popular and scientific essays., New York, Ranney
  5. Bouchard, Charles (1906), Lectures on Auto-Intoxication in Disease: Or, Self-Poisoning of the Individual, Philadelphia, F. A. Davis Company
  6. “The Conquest of Constipation”. JAMA: The Journal of the American Medical Association. 81 (2): 158. 1923. doi:10.1001/jama.1923.02650020076035. ISSN 0098-7484.
  7. 7.0 7.1 7.2 Lane WA (1913). “An Address ON CHRONIC INTESTINAL STASIS: Delivered at the North-East London Post-Graduate College”. Br Med J. 2 (2757): 1125–8. PMC 2346322. PMID 20766844.
  8. “The Lazy Colon. Newer Methods and Latest Advances of Science in the Treatment of Constipation”. JAMA: The Journal of the American Medical Association. 90 (26): 2134. 1928. doi:10.1001/jama.1928.02690530062033. ISSN 0098-7484.
  9. Bilik, Samuel Ernest (1928), The trainers bible, New York city, Athletic trainers supply Co.
  10. Burkitt, D. P. (1981). Western diseases, their emergence and prevention. Cambridge, Mass: Harvard University Press. ISBN 978-0674950207.

Template:WH Template:WS

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

Constipation may be classified according to etiology into seven subtypes include gastrointestinal, neurologic, metabolic, endocrine, psychiatric, drug-induced, and idiopathic.

Classification

Constipation may be classified according to etiology into five subtypes:[1][2]

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Constipation
classification
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Etiology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neurologic
 
Metabolic
 
Endocrine
 
 
 
 
Gastrointestinal
 
 
 
 
Psychiatric
 
Drugs
 
Idiopathic
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obstruction
 
Aganglionosis
 
Idiopathic megacolon
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hirschprung disease
 
Chagas disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple sclerosis
Parkinson’s disease
Spinal cord injury
 
Hypercalcemia
Hypomagnesemia
Porphyria
Hypokalemia
 
Hypothyroidism
Diabetes mellitus
Panhypopituitarism
 
 
 
 
 
 
 
 
 
 
 
Depression
Eating disorder
 
Analgesics
Anticholinergics
Cation-containing agents
Neuron targeting agents
 
• Normal colonic transit
• Slow colonic transit
• Dyssynergic defecation

References

  1. Hinton JM, Lennard-Jones JE (1968). “Constipation: definition and classification”. Postgrad Med J. 44 (515): 720–3. PMC 2466679. PMID 5705375.
  2. Gray JR (2011). “What is chronic constipation? Definition and diagnosis”. Can J Gastroenterol. 25 Suppl B: 7B–10B. PMC 3206562. PMID 22114751.

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

About 1.5 liter fluid enters the colon from small intestine every day. Colon only excrete out 200-400 mL stool. The defecation process consist of three important stages, include filling of the rectum, sensation of rectum fullness, and relaxation of pelvic floor muscles in a coordinated fashion. Primary constipation is caused by anorectal and colonic problems, while secondary constipation is caused by organic and metabolic diseases or medications. Diseases that disturb the nervous system may lead to constipation, such as diabetes mellitus, autonomic neuropathy, Chagas’ disease, and Hirschsprung’s disease. Chronic use of the laxative may lead to melanosis coli, which is identified by hyperpigmentation and brownish discoloration of colonic mucosa. The primary histopathological finding in melanosis coli is brown granular pigment in lamina propria.

Pathophysiology

Colonic Function

Defecation

Pathogenesis

Primary constipation

Secondary constipation

Group Drug Alternatives
Antihypertensives Clonidine
Calcium channel blockers
Ganglionic blockers
Antidepressants Tricyclic antidepressants
Cation-containing drugs Oral iron supplementation
Aluminum-containing drugs Sucralfate
Antacids
Analgesics Opiates
Cannabinoids
Anti-Parkinson
Antiepileptic
Antipsychotic
Antihistamines
  • Replaced with other groups
Antispasmodics
Vinca alkaloids

Genetics

  • Genetic studies have shown the role of genetics in childhood constipation by various mechanisms.
  • Genes involved in the pathogenesis of childhood constipation and related diseases are as following:[24]
Group Gene OMIM/Chromosome Syndrome Other manifestations
Autonomic nervous system GFAP 203450/17q21 Alexander disease
LMNB1 169500/5q23 Cavitating leukodystrophy – autonomic failure
PHOX2B 209880/4p12 Congenital central hypoventilation syndrome
HSN2 201300/12p13 Hereditary sensory and autonomic neuropathy type II and III
IKBKAP 223900/9q31
MECP2 300005/Xq28 MECP2 duplication
SCN9A 167400/2q24 Paroxysmal extreme pain disorder
TCF4 610954/18q21 Pitt-Hopkins syndrome
NRXN1 610954/2p16.3
Innervation ATRX 301040/Xq13 Alpha-thalassemia mental retardation syndrome
RET 162300/10q11 MEN2B
ZEB2 235730/2q22 Mowat-Wilson syndrome
HPSE2 236730/10q24 Ochoa syndrome
Muscular COL4A5 308940/Xq22 Alport syndrome with diffuse leiomyomatosis
COL4A6
PTRF-CAVIN 613327/17q21 Congenital generalized lipodystrophy, type 4
DES 601419/2q35 Desmin-related myopathy
SCN4A 170500/17q23 Hyperkalemic periodic paralysis (HYPP)
  • Episodic flaccid generalized muscle weakness
ZNF9 160900/3q21 Myotonic dystrophy
DMPK 602668/19q13
SMN1 253300/5q12 Spinal muscular atrophy
AXPC1 609033/1q31 Posterior column ataxia with retinitis pigmentosa
CBP 180849/16p13 Rubinstein-Taybi syndrome
EP300 180849/22q13
HUWE1 300706/Xp11 Turner mental retardation syndrome
UPF3B 300676/Xq25 X-linked syndromic mental retardation -14
Electrolyte disturbance SLC12A3 263800/16q13 Gitelman syndrome
SLC6A8 300036/Xq28 Creatinine transporter defect
CASR 239200/3q21 Hyperparathyroidismneonatal familial
AVPR2 304800/Xq28 Nephrogenic diabetes insipidus
SPINK5 256500/5q32 Netherton syndrome
Malformation HLXB9 176450/7q36 Currarino syndrome
MED12 305450/Xq13 FG syndrome
FLNA 305450/Xq28
SIX3 157170/2p21 Holoprosencephaly
VANGL1 600145/1p13 Sacral defect with anterior meningocele

Associated Conditions

Associated conditions with constipation are included:

Gross Pathology

  • On gross pathology, there is no finding related to constipation.

Microscopic Pathology

Melanosis coli with brown granular pigments, By Ed Uthman from Houston, TX, USA – Uploaded by CFCF, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=30104213
Melanosis coli, By myself (Alex_brollo) – Slide files from Hospital of Monfalcone (Italy), CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=1221399
Melanosis coli in laxative abusing patient, By Ed Uthman from Houston, TX, USA – Melanosis coliUploaded by CFCF, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=30104214

References

  1. 1.0 1.1 Sleisenger, Marvin (2010). Sleisenger and Fordtran’s gastrointestinal and liver disease : pathophysiology, diagnosis, management. Philadelphia: Saunders/Elsevier. ISBN 9781437727678.
  2. 2.0 2.1 Andrews CN, Storr M (2011). “The pathophysiology of chronic constipation”. Can J Gastroenterol. 25 Suppl B: 16B–21B. PMC 3206564. PMID 22114753.
  3. Southwell BR, Clarke MC, Sutcliffe J, Hutson JM (2009). “Colonic transit studies: normal values for adults and children with comparison of radiological and scintigraphic methods”. Pediatr. Surg. Int. 25 (7): 559–72. doi:10.1007/s00383-009-2387-x. PMID 19488763.
  4. Dinning PG, Smith TK, Scott SM (2009). “Pathophysiology of colonic causes of chronic constipation”. Neurogastroenterol. Motil. 21 Suppl 2: 20–30. doi:10.1111/j.1365-2982.2009.01401.x. PMC 2982774. PMID 19824935.
  5. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Taché Y, Wood JD (2006). “Fundamentals of neurogastroenterology: basic science”. Gastroenterology. 130 (5): 1391–411. doi:10.1053/j.gastro.2005.11.060. PMID 16678554.
  6. Bharucha AE (2006). “Pelvic floor: anatomy and function”. Neurogastroenterol. Motil. 18 (7): 507–19. doi:10.1111/j.1365-2982.2006.00803.x. PMID 16771766.
  7. Rao SS (2010). “Advances in diagnostic assessment of fecal incontinence and dyssynergic defecation”. Clin. Gastroenterol. Hepatol. 8 (11): 910–9. doi:10.1016/j.cgh.2010.06.004. PMC 2964406. PMID 20601142.
  8. Rao SS, Camilleri M, Hasler WL, Maurer AH, Parkman HP, Saad R, Scott MS, Simren M, Soffer E, Szarka L (2011). “Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies”. Neurogastroenterol. Motil. 23 (1): 8–23. doi:10.1111/j.1365-2982.2010.01612.x. PMID 21138500.
  9. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006). “Functional bowel disorders”. Gastroenterology. 130 (5): 1480–91. doi:10.1053/j.gastro.2005.11.061. PMID 16678561.
  10. Ashraf W, Park F, Lof J, Quigley EM (1996). “An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation”. Am. J. Gastroenterol. 91 (1): 26–32. PMID 8561138.
  11. Cash BD, Chey WD (2005). “Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation”. Aliment. Pharmacol. Ther. 22 (11–12): 1047–60. doi:10.1111/j.1365-2036.2005.02696.x. PMID 16305718.
  12. Preston DM, Lennard-Jones JE (1986). “Severe chronic constipation of young women: ‘idiopathic slow transit constipation. Gut. 27 (1): 41–8. PMC 1433176. PMID 3949236.
  13. Bassotti G, Roberto GD, Sediari L, Morelli A (2004). “Toward a definition of colonic inertia”. World J. Gastroenterol. 10 (17): 2465–7. PMC 4572142. PMID 15300885.
  14. He CL, Burgart L, Wang L, Pemberton J, Young-Fadok T, Szurszewski J, Farrugia G (2000). “Decreased interstitial cell of cajal volume in patients with slow-transit constipation”. Gastroenterology. 118 (1): 14–21. PMID 10611149.
  15. Tzavella K, Riepl RL, Klauser AG, Voderholzer WA, Schindlbeck NE, Müller-Lissner SA (1996). “Decreased substance P levels in rectal biopsies from patients with slow transit constipation”. Eur J Gastroenterol Hepatol. 8 (12): 1207–11. PMID 8980942.
  16. Rao SS, Ozturk R, Laine L (2005). “Clinical utility of diagnostic tests for constipation in adults: a systematic review”. Am. J. Gastroenterol. 100 (7): 1605–15. doi:10.1111/j.1572-0241.2005.41845.x. PMID 15984989.
  17. 17.0 17.1 Rao SS (2008). “Dyssynergic defecation and biofeedback therapy”. Gastroenterol. Clin. North Am. 37 (3): 569–86, viii. doi:10.1016/j.gtc.2008.06.011. PMC 2575098. PMID 18793997.
  18. Fosnes GS, Lydersen S, Farup PG (2011). “Constipation and diarrhoea – common adverse drug reactions? A cross sectional study in the general population”. BMC Clin Pharmacol. 11: 2. doi:10.1186/1472-6904-11-2. PMC 3049147. PMID 21332973.
  19. Simonson W, Han LF, Davidson HE (2011). “Hypertension treatment and outcomes in US nursing homes: results from the US National Nursing Home Survey”. J Am Med Dir Assoc. 12 (1): 44–9. doi:10.1016/j.jamda.2010.02.009. PMID 21194659.
  20. Dolder C, Nelson M, Stump A (2010). “Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients”. Drugs Aging. 27 (8): 625–40. doi:10.2165/11537140-000000000-00000. PMID 20658791.
  21. Talley NJ, Jones M, Nuyts G, Dubois D (2003). “Risk factors for chronic constipation based on a general practice sample”. Am. J. Gastroenterol. 98 (5): 1107–11. doi:10.1111/j.1572-0241.2003.07465.x. PMID 12809835.
  22. Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F (2010). “Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment”. Eur Rev Med Pharmacol Sci. 14 (12): 1045–50. PMID 21375137.
  23. Takahashi T, Matsuda K, Kono T, Pappas TN (2003). “Inhibitory effects of hyperglycemia on neural activity of the vagus in rats”. Intensive Care Med. 29 (2): 309–11. doi:10.1007/s00134-002-1580-3. PMID 12594591.
  24. Peeters B, Benninga MA, Hennekam RC (2011). “Childhood constipation; an overview of genetic studies and associated syndromes”. Best Pract Res Clin Gastroenterol. 25 (1): 73–88. doi:10.1016/j.bpg.2010.12.005. PMID 21382580.

Template:WH Template:WS

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2], Eiman Ghaffarpasand, M.D. [3]

Overview

Constipation in adults may be due to side effects of medications, such as antispasmodics, anticholinergics, analgesics; or may be associated with systemic disorders, such as diabetes mellitus and hypothyroidism. Idiopathic constipation should be considered once the secondary causes are ruled out and it may be associated with normal or slow colonic transit, dysfunction in defecation, or both. Constipation in childhood often resolves with age after proper guidance regarding diet, toilet training, and toileting behaviors.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. These conditions include the followings:[1]

Common Causes

Common causes of constipation include:[2][3][4][5][6]

Less Common Causes

Less common causes of constipation include:[7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]

Causes by Organ System

Cardiovascular Iliac artery aneurysm, Superior mesenteric artery occlusion.
Chemical / poisoning Atropine poisoning, Lead poisoning, Opium poisoning.
Dermatologic Dermatitis herpetiformis.
Drug Side Effect

5-HT3 antagonist, 5-hydroxytryptophan, Acamprosate, Acebutolol, Acetaminophen, Aldesleukin, Alendronate, Alfentanil, Alfuzosin, Alosetron, Alprazolam, Aluminium hydroxide, Amiodarone, Amitriptyline, Amlodipine, Amobarbital, Anagrelide, Anastrozole, Aprepitant, Aripiprazole, Atorvastatin, Atovaquone, Atropine, Auranofin, Axitinib, Azacitidine Barium sulfate, Basiliximab, Benzatropine, Benzonatate, Bepridil, Beta blockers, Bezafibrate, Bicalutamide, Bile acid sequestrant, Bortezomib, Bromocriptine, Buspirone, Busulfan, Butabarbital, Butorphanol, Calcitriol, Calcium carbonate, Capecitabine, Caspofungin acetate, Carbamazepine, Carbidopa, Carboplatin, Carfilzomib, Carteolol, Cerivastatin, Cetuximab, Chlordiazepoxide, Chloropyramine, Chlorpromazine, Chlorpropamide, Cholestyramine, Cidofovir, Cimetidine, Cisapride, Citalopram, Cladribine, Clobazam, Clofarabine, Clomipramine, Clonazepam, Clonidine, Clorazepate, Clozapine, Codeine, Colesevelam, Colestipol, Colofac, Crizotinib, Cyclizine, Cyclobenzaprine, Cytarabine liposome Daptomycin, Darbepoetin alfa, Darifenacin, Darunavir, Desipramine, Desvenlafaxine, Dextroamphetamine, Dextropropoxyphene, Diacetyldihydromorphine, Diazepam, Dicyclomine, Diethylcathinone, Diflunisal, Dihydroetorphine, Diltiazem, Dimenhydrinate, Diphenhydramine, Disopyramide, Diuretic, Dolasetron, Dolasetron, Doripenem, Dosulepin hydrochloride, Doxepin, Droperidol, Duloxetine, Efavirenz, Enfuvirtide, Enzalutamide, Epoetin alfa, Eribulin, Esomeprazole, Estazolam, Estradiol, Ethcathinone, Ethosuximide, Ethylmorphine, Etodolac, Etoposide, Everolimus, Famotidine, Felbamate, Felodipine, Fenofibrate, Fenoprofen, Fentanyl, Ferrous sulfate, Fesoterodine, Fludarabine phosphate, Fluorouracil, Fluoxetine, Fluphenazine, Flurazepam, Flurbiprofen, Fluvoxamine, Fulvestrant, Furosemide, Gabapentin, Ganciclovir, Gatifloxacin, Gemcitabine, Gemfibrozil, Glipizide, Glycopyrrolate, Granisetron, Guanethidine, Guanfacine, H2 antagonist, Haloperidol, Hexamethonium, Histone deacetylase inhibitors, Hydralazine, Hydrocodone, Hydrocodone bitartrate and Homatropine methylbromide, Hydroxyurea, Hydroxyzine, Hyoscyamine, Hydrochlorothiazide, Ibandronate, Imatinib, Imipramine, Indomethacin, Insulin lispro, Interferon beta-1b, Ipratropium, Irinotecan hydrochloride, Iron supplements, Isocarboxazid, Isradipine, Itraconazole, Ivermectin, Kaolin, Ketorolac tromethamine, Lacidipine, Lamivudine, Lamotrigine, Lansoprazole, Lanthanum, Leflunomide, Lenalidomide, Letrozole, Leuprolide, Levalbuterol, Levetiracetam, Levodopa, Levomethadyl, Levorphanol, Linezolid, Lofepramine, Lomotil, Lorcaserin, Loperamide, Loprazolam, Lorazepam, Lovastatin, Lovaza, Loxapine, Magaldrate, Mebendazole, Meclizine, Meclofenamate, Mefenamic acid, Meperidine, Meropenem, Mesalamine, Mesna, Mesoridazine, Metformin, Methadone, Methsuximide, Methyprylon, Metoprolol, Mifepristone, Milnacipran hydrochloride, Misoprostol, Modafinil, Morphine, Motofen, Nabumetone, Naproxen sodium, Nateglinide, Nefazodone, Netupitant and palonosetron, Nicardipine, Nifedipine, Nilotinib, Nilutamide, Nimodipine, Nisoldipine, Nizatidine, Nortriptyline, Olanzapine, Omeprazole, Ondansetron, Oxaliplatin, Oxazepam, Oxcarbazepine, Oxybutynin, Oxycodone, Palonosetron, Pamidronate, Pancrelipase, Paroxetine, Peginterferon alfa-2b, Pemetrexed, Pentamidine Isethionate, Pergolide, Perphenazine, Pethidine, Phenelzine, Phentermine, Phenytoin, Pholcodine, Pimozide, Piperacillin sodium, Piroxicam, Posaconazole, Pramipexole, Prazepam, Prazosin, Prednisolone, Pregabalin, Procarbazine, Prochlorperazine, Procyclidine, Progesterone, Promethazine, Propafenone, Propantheline, Propoxyphene, Propranolol, Protriptyline, Quetiapine, Rabeprazole, Ranitidine, Ranolazine, Rasagiline, Rasburicase, Reboxetine, Repaglinide, Ribavirin, Rilmenidine, Risperidone, Rivastigmine, Ropinirole, Rosuvastatin, Sacrosidase, Saquinavir, Scopolamine, Scopolamine, Secobarbital, Selegiline, Sertraline, Sevelamer, Sibutramine, Siltuximab, Simethicone, Simvastatin, Sirolimus, Sitaxsentan, Sorafenib, Sotalol, Sucralfate, Sufentanil, Sulindac, Sunitinib, Suxamethonium chloride, Tacrolimus, Tamoxifen, Tapentadol, Tegaserod, Temazepam, Temozolomide, Terazosin, Teriparatide, Tetraferric tricitrate decahydrate, Thalidomide, Thioridazine hydrochloride, Thiothixene, Tianeptine, Tiludronate, Tinidazole, Tiotropium, Tolterodine, Tolmetin, Topiramate, Topotecan, Trametinib dimethyl sulfoxide, Tranylcypromine, Tretinoin, Triazolam, Triclofos, Trifluoperazine, Trihexyphenidyl, Trimethadione, Trimipramine, Tropisetron, Trospium, Valganciclovir hydrochloride, Valproic acid, Venlafaxine, Verapamil, Vicodin, Vigabatrin, Viloxazine, Vinblastine, Vincristine, Vincristine sulfate liposome, Vindesine, Vinorelbine, Vorinostat, Zaleplon, Zidovudine, Zileuton, Ziprasidone, Zoledronic acid, Zolpidem, Zonisamide, Zotepine.

Ear Nose Throat No underlying causes
Endocrine

Conn’s syndrome, Diabetes mellitus, Glucagonoma, Hashimoto’s thyroiditis, Hyperparathyroidism, Hypothyroidism, Multiple endocrine neoplasia, Multiple endocrine neoplasia type 1, Multiple endocrine neoplasia type 2, Myxedema, Panhypopituitarism, Parathyroid adenoma, Pheochromocytoma, Primary parathyroid hyperplasia, Pseudohypoparathyroidism.

Environmental Cow’s milk intolerance
Gastroenterologic

Anal atresia, Anal carcinoma, Ascites, bowel adhesion, Bowel obstruction, cap polyposis, Celiac disease, Chronic amebiasis, Colectomy, Colonic stricture, Colorectal cancer, Congenital malformation, Corrosive enemas, Crohn’s disease, Diverticular stricture, Diverticulitis, Enterocele, Eosinophilic colitis, Extrinsic compression, Gastroptosis, Hernia, Hirschsprung’s disease, Ileus, Imperforate anus, Inflammatory bowel disease, Intraabdominal/pelvic tumors, Intussusception, Irritable bowel syndrome, Ischemic colitis, Megacolon, Megarectum, Ogilvie’s syndrome, Painful defecation, Paralytic ileus, Pelvic masses, Pelvic tumors, Perianal abscess, Proctitis, Rectal cancer, Rectal prolapse, Rectal ulcer, Rectocele, Ulcerative colitis, Visceral myopathies, Volvulus, Wandering spleen.

Genetic

Batten disease, Berdon syndrome, Cerebral palsy, Cornelia de Lange syndrome, Cystic fibrosis, Down syndrome, Gastroschisis, Hereditary coproporphyria, Hereditary internal anal sphincter myopathy, Megacolon, Megarectum, Prune belly syndrome.

Hematologic

Acute intermittent porphyria, Amyloidosis, Hereditary coproporphyria, Iron deficiency anemia.

Iatrogenic

Adjustable gastric band, Colectomy, painful defecation, Peritoneal dialysis, Postoperative complications, Postoperative ileus, Toilet training issues, Upper gastrointestinal series.

Infectious Disease

Blastocystosis, Botulism, Chagas disease, Chronic amebiasis, Hookworm, Lassa fever, Lymphogranuloma venereum, Syphilis, Tuberculosis, Typhoid fever, Opisthorchis infection, Polio.

Musculoskeletal / Ortho Ankylosing spondylitis, Guillain-Barre syndrome, Lambert-Eaton myasthenic syndrome, Muscular dystrophy, Osteitis fibrosa cystica, Paraplegia, Spinal cord injury, Spinal cord tumor.
Neurologic

Amyotrophic lateral sclerosis, Autonomic neuropathy, Cerebral palsy, Chagas disease, Chronic inflammatory demyelinating polyneuropathy, Diabetes mellitus, Guillain-Barre syndrome, Hirschsprung’s disease, Intestinal neuronal dysplasia, Lambert-Eaton myasthenic syndrome, Meningocele, Multiple sclerosis, Muscular dystrophy, Neurofibromatosis, Occult spinal dysraphism sequence, Paraplegia, Parkinson’s disease, Progressive supranuclear palsy, Pseduoobstruction, Scleroderma, Spina bifida, Spinal cord injury, Spinal cord lesions, Static encephalopathy, Tabes dorsalis, Tethered spinal cord syndrome.

Nutritional / Metabolic

Cow’s milk intolerance, Food intolerance, Hypercalcemia, Hypervitaminosis D, Hypokalemia, Iron deficiency anemia, Ketogenic diet, Lack of fiber, Low residue diet, Milk-alkali syndrome, Severe dehydration, Starvation.

Obstetric/Gynecologic Childbirth, Complication of pregnancy, Extremely low birth weight, Ovarian cancer, Rectovaginal or bowel endometriosis, Uterine fibroid.
Oncologic Colorectal cancer, Intraabdominal/pelvic tumors, Multiple endocrine neoplasia (MEN 2b), Neuroblastoma, Ovarian cancer, Parathyroid adenoma, Rectal carcinoma, Renal cell carcinoma, Sacrococcygeal teratoma, Spinal cord tumor, Stomach cancer, Uterine fibroid.
Opthalmologic No underlying causes
Overdose / Toxicity Acamprosate, Amiodarone, Atropine, Carboplatin, Fentanyl, Phenytoin, Hypervitaminosis D, Haloperidol.
Psychiatric

Anorexia nervosa, Autism, Bipolar disorder, Eating disorder, Emotional stress, Major depression, Obsessive compulsive disorder, Pseudocyesis, Psychosis.

Pulmonary Cystic fibrosis.
Renal / Electrolyte Hypercalcemia, Hypokalemia, Renal cell carcinoma, Severe dehydration, Uremia.
Rheum / Immune / Allergy

Amyotrophic lateral sclerosis, Ankylosing spondylitis, Chronic inflammatory demyelinating polyneuropathy, Cow’s milk intolerance, Food intolerance, Guillain-Barre syndrome, Lambert-Eaton myasthenic syndrome, Rett syndrome, Scleroderma.

Sexual Tabes dorsalis.
Trauma Spinal cord injury.
Urologic Urogenital neoplasm.
Miscellaneous

Dietary pattern change, Dieting, Extended bed rest, Functional constipation, Idiopathic, Normal aging, Smoking cessation, SSRI discontinuation syndrome, Travel constipation.

Causes in Alphabetical Order

References

  1. Hennessey A, Robertson NP, Swingler R, Compston DA (1999). “Urinary, faecal and sexual dysfunction in patients with multiple sclerosis”. J Neurol. 246 (11): 1027–32. PMID 10631634.
  2. Roma E, Adamidis D, Nikolara R, Constantopoulos A, Messaritakis J (1999). “Diet and chronic constipation in children: the role of fiber”. J Pediatr Gastroenterol Nutr. 28 (2): 169–74. PMID 9932850.
  3. Caldarella MP, Milano A, Laterza F; et al. (2005). “Visceral sensitivity and symptoms in patients with constipation- or diarrhea-predominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion”. Am. J. Gastroenterol. 100 (2): 383–9. doi:10.1111/j.1572-0241.2005.40100.x. PMID 15667496.
  4. “Nicotine withdrawal symptoms:Constipation”. helpwithsmoking.com. 2005. Retrieved 2007-06-29.
  5. Langston JW (2006). “The Parkinson’s complex: parkinsonism is just the tip of the iceberg”. Ann Neurol. 59 (4): 591–6. doi:10.1002/ana.20834. PMID 16566021.
  6. Stadtler AC, Gorski PA, Brazelton TB (1999). “Toilet training methods, clinical interventions, and recommendations. American Academy of Pediatrics”. Pediatrics. 103 (6 Pt 2): 1359–68. PMID 10353954.
  7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D; et al. (2003). “A phase 2 study of bortezomib in relapsed, refractory myeloma”. N Engl J Med. 348 (26): 2609–17. doi:10.1056/NEJMoa030288. PMID 12826635.
  8. Bookman ID, Redston MS, Greenberg GR (2004). “Successful treatment of cap polyposis with infliximab”. Gastroenterology. 126 (7): 1868–71. PMID 15188181.
  9. Figueroa JJ, Dyck PJ, Laughlin RS, Mercado JA, Massie R, Sandroni P; et al. (2012). “Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy”. Neurology. 78 (10): 702–8. doi:10.1212/WNL.0b013e3182494d66. PMC 3306161. PMID 22357716.
  10. Stanghellini V, Cogliandro RF, De Giorgio R, Barbara G, Morselli-Labate AM, Cogliandro L; et al. (2005). “Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study”. Clin Gastroenterol Hepatol. 3 (5): 449–58. PMID 15880314.
  11. Kárpáti S (2011). “An exception within the group of autoimmune blistering diseases: dermatitis herpetiformis, the gluten-sensitive dermopathy”. Dermatol Clin. 29 (3): 463–8, x. doi:10.1016/j.det.2011.03.019. PMID 21605813.
  12. Kühnel A, Gross U, Doss MO (2000). “Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients”. Clin Biochem. 33 (6): 465–73. PMID 11074238.
  13. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES; et al. (2009). “Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report”. Haematologica. 94 (11): 1618–22. doi:10.3324/haematol.2009.008607. PMC 2770976. PMID 19608677.
  14. Levi N, Schroeder TV (1998). “Isolated iliac artery aneurysms”. Eur J Vasc Endovasc Surg. 16 (4): 342–4. PMID 9818012.
  15. Favier R, Jondeau K, Boutard P, Grossfeld P, Reinert P, Jones C; et al. (2003). “Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases”. Thromb Haemost. 90 (5): 893–7. doi:10.1267/THRO03050893. PMID 14597985.
  16. O’Suilleabhain P, Low PA, Lennon VA (1998). “Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates”. Neurology. 50 (1): 88–93. PMID 9443463.
  17. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF (1996). “Milnacipran and selective serotonin reuptake inhibitors in major depression”. Int Clin Psychopharmacol. 11 Suppl 4: 41–6. PMID 8923126.
  18. Jetmore AB, Timmcke AE, Gathright JB, Hicks TC, Ray JE, Baker JW (1992). “Ogilvie’s syndrome: colonoscopic decompression and analysis of predisposing factors”. Dis Colon Rectum. 35 (12): 1135–42. PMID 1473414.
  19. Partin JC, Hamill SK, Fischel JE, Partin JS (1992). “Painful defecation and fecal soiling in children”. Pediatrics. 89 (6 Pt 1): 1007–9. PMID 1594338.
  20. Margulies A, Metman EH, Girard JJ, Dorval ED, Bertrand J (1986). “[Severe constipation indicative of pseudohypoparathyroidism and resolved after normalization of the blood calcium]”. Ann Gastroenterol Hepatol (Paris). 22 (5): 271–2. PMID 3777869.
  21. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I; et al. (2012). “Sirolimus and secondary skin-cancer prevention in kidney transplantation”. N Engl J Med. 367 (4): 329–39. doi:10.1056/NEJMoa1204166. PMID 22830463.
  22. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B; et al. (2010). “Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma”. Blood. 116 (9): 1405–12. doi:10.1182/blood-2009-08-237974. PMID 20448107.
  23. Sforzini C, Milani D, Fossali E, Barbato A, Grumieri G, Bianchetti MG; et al. (2002). “Renal tract ultrasonography and calcium homeostasis in Williams-Beuren syndrome”. Pediatr Nephrol. 17 (11): 899–902. doi:10.1007/s00467-002-0889-z. PMID 12432430.
  24. Peeters B, Noens I, Philips EM, Kuppens S, Benninga MA (2013). “Autism spectrum disorders in children with functional defecation disorders”. J Pediatr. 163 (3): 873–8. doi:10.1016/j.jpeds.2013.02.028. PMID 23522863.
  25. Yang LP, Plosker GL (2008). “Desvenlafaxine extended release”. CNS Drugs. 22 (12): 1061–9. doi:10.2165/0023210-200822120-00008. PMID 18998743.
  26. Kikuta S, Asakage T, Nakao K, Sugasawa M, Kubota A (2008). “The aggravating factors of hyperammonemia related to 5-fluorouracil infusion–a report of two cases”. Auris Nasus Larynx. 35 (2): 295–9. doi:10.1016/j.anl.2007.04.012. PMID 17826933.
  27. Legha SS (1986). “Vincristine neurotoxicity. Pathophysiology and management”. Med Toxicol. 1 (6): 421–7. PMID 3540519.

Template:WikiDoc Sources

Differentiating Constipation from Other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

Diseases that cause constipation should differentiate from each others, such as malignancy, diabetic autonomic neuropathy, irritable bowel syndrome, rectocele, fissure, anismus, systemic sclerosis, hypothyroidism, Parkinson’s disease, multiple sclerosis, hypomagnesemia, hypocalcemia, and depression.

Differentiating Constipation from Other Diseases

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight loss>10 lb
FHx of CRC
•Acute onset in elderly
Hematochezia
Iron deficiency anemia
•Positive OB
 
 
 
 
 
 
 
 
 
 
 
Analgesic
Anticholinergic
••Antihistamines
••Antispasmodics
••Antidepressants
••Antipsychotics
Cation-containing agent
••Iron supplements
••Aluminum (antacids, sucralfate)
••Barium
Neuron targeting agents
••Opiates
••Antihypertensive
••Ganglionic blocker
••Calcium channel blockers
••5-HT3 antagonist
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alarm signs
 
 
 
 
 
 
 
Drugs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Constipation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abdominal pain
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Irritable bowel syndrome
Malignancy
Diabetic autonomic neuropathy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypothyroidism
Hypomagnesemia
Hypocalcemia
Systemic sclerosis
Multiple sclerosis
Parkinson’s disease
Depression
Fissure
Anismus
Rectocele
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight loss
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anal pain
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
 
 
NO
 
 
 
 
 
 
YES
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Irritable bowel syndrome
Diabetic autonomic neuropathy
 
 
 
 
 
 
Fissure
Anismus
Rectocele
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypothyroidism
Hypomagnesemia
Hypocalcemia
Systemic sclerosis
Multiple sclerosis
Parkinson disease
Depression
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polyuria
Polydipsia
Polyphagia
 
 
 
 
 
 
Mass protrusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dry skin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
NO
 
YES
 
 
 
NO
 
 
 
 
 
YES
 
 
 
 
 
 
 
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fissure
Anismus
 
 
 
 
 
Hypothyroidism
Systemic sclerosis
 
 
 
 
 
 
 
 
 
 
Hypomagnesemia
Hypocalcemia
Multiple sclerosis
Parkinson’s disease
Depression
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rectal bleeding
 
 
 
 
 
Dysphagia
 
 
 
 
 
 
 
 
 
 
Neurologic symptoms
(tremor, abnormal gait)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
NO
 
YES
 
NO
 
 
 
YES
 
 
 
 
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple sclerosis
Parkinson disease
 
 
 
 
 
 
 
Hypomagnesemia
Hypocalcemia
Depression
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basal ganglia atrophy in MRI
 
 
 
 
 
 
 
Electrolyte disturbance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
NO
 
YES
 
YES
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Malignancy
 
Diabetic autonomic neuropathy
 
Irritable bowel syndrome
 
Rectocele
 
Fissure
 
Anismus
 
Systemic sclerosis
 
Hypothyroidism
 
Parkinson’s disease
 
Multiple sclerosis
 
Hypomagnesemia
 
Hypocalcemia
 
Depression
 

Differentiating Diseases that Cause Constipation

To review the differential diagnosis of Constipation and Abdominal pain, click here.

To review the differential diagnosis of Constipation and Anal pain, click here.

To review the differential diagnosis of Constipation and Rectal bleeding, click here.

To review the differential diagnosis of Constipation and Weight loss, click here.

To review the differential diagnosis of Constipation and Tremor, click here.


Diseases History and Symptoms Physical Examination Laboratory Findings Other Findings Diagnostic study of choice
Electrolyts

[Ca, K, Mg]

Biochemical tests
GI symptoms Extra GI symptoms Abnormal gait Anal protruding mass DRE Deep tendon reflex FBS TSH
Dysphagia Abdominal pain Anal pain Rectal bleeding Weight loss Polyphagia, Polyuria, Polydipsia Dry skin Tremor
Gastrointestinal diseases Malignancy +/- + ++ Empty rectum Normal Normal Normal Normal
Irritable bowel syndrome (IBS) + +/- Normal Normal Normal Normal Normal
Rectocele + Bulging rectum Normal Normal Normal Normal
Anal fissure +++ + Increased sphincter tone Normal Normal Normal Normal
Anismus + Increased sphincter tone Normal Normal Normal Normal
Diverticulosis + + Normal Normal Normal Normal Normal
Neurogenic diseases Diabetic autonomic neuropathy + ++ +/- +/- Normal Normal ↑↑ Normal
Anorexia nervosa ++ +/- Normal Normal ↓ Electrolytes Normal
Parkinson’s disease +/- ++ + Normal ↑↑ Normal Normal Normal
Multiple sclerosis + + + Normal ↓↑ Normal Normal Normal
  • Brain MRI
  • CSF biochemical profile
Depression + Normal Normal Normal Normal Normal
Hirschsprung disease + + + Blood tinged glove Normal Normal Normal Normal
Cerebral palsy + + + + Normal Normal Normal Normal
Chagas disease + + Normal Normal Normal Normal
Endocrine diseases Hypothyroidism + Normal ↓↓ Normal Normal ↑↑
Cystic fibrosis + + Normal Normal Normal Normal Normal
Lead poisoning +++ + Normal Normal Normal Normal Normal
Pheochromocytoma + Normal Normal Normal Normal Normal
Panhypopituitarism Normal Normal Normal Normal
Electrolyte disturbances Hypomagnesemia + + Normal ↓↓ Mg Normal Normal
  • Plasma Mg level
Hypocalcemia/Hypercalcemia + Normal ↓Ca/Ca Normal Normal
  • Plasma Ca level
Hypokalemia + +/- Normal ↓K Normal Normal
  • Plasma K level
Systemic diseases Pregnancy Normal Normal Normal Normal Normal
Systemic sclerosis + + Normal Normal Normal Normal Normal

References

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

The incidence of constipation is approximately 16,666 per 100,000 individuals in general population (one in every six). The prevalence of constipation is approximately 2,000 to 28,000 per 100,000 individuals in general population. It is estimated that 4-56 million people are suffering from constipation in United States. The prevalence of constipation is approximately 1,900 to 27,200 (with an average of 14,800) per 100,000 individuals in North America. The general decline in 10-year survival rate of people with functional constipation is about 12%, comparing to normal population. The incidence of constipation increases with age. The non-White to White ratio of involving in constipation is from 1.13 to 2.89 (Mean 1.68, Median 1.41). Females are more commonly affected by constipation than males. The female to male ratio is approximately 2.2 to 1. Developing countries with lower income show higher prevalence of constipation rather than developed countries with higher income. Educational years in the population show an inverse relationship with prevalence of constipation.

Epidemiology and Demographics

Incidence

  • The incidence of constipation is approximately 16,666 per 100,000 individuals in general population (one in every six).[1]

Prevalence

  • The prevalence of constipation is approximately 2,000 to 28,000 per 100,000 individuals in general population.[2][3]
  • It is estimated that 4-56 million people are suffering from constipation in United States.
  • The prevalence of constipation is approximately 1,900 to 27,200 (with an average of 14,800) per 100,000 individuals in North America.[4]
Year Sample size Diagnosis Prevalence

(per 100,000 individuals)

1964 890,394 Self-report 27,100
1971-1975 15,014 Self-report 12,800
1971-1975 11,024 Self-report 15,800
1983-1987 Not reported Self-report 1,900
1989 42,375 Self-report 3,400
1991 835 Self-report

OR

< 3 defecations per week

17,400
1993 690 Self-report 5,000
ROME I functional constipation (FC) 19,200
ROME I outlet obstruction (OD) 11,000
1993 5,430 ROME I functional constipation (FC) 3,600
ROME I Dyschezia 13,800
1997 10,018 ROME II, FC, OD, or IBS-C (irritable bowel syndrome, constipation type) 14,700
2000 1,149 Self-report 27,200
ROME I 16,700
ROME II 14,900

Case-fatality rate/Mortality rate

  • The case-fatality rate of constipation is very low.
  • Very long-term constipation can cause death in elderly.
  • Persistent and transient constipation can increase the mortality rate up to 2.8% and 2%, respectively, rather than people without constipation.[5]
  • The general decline in 10-year survival rate of people with functional constipation is about 12%, comparing to normal population.[6]

Age

  • Patients of all age groups may develop constipation.
  • The incidence of constipation increases with age.[7]
Type of diagnosis Age group Prevalence

(per 100,000 individuals)

Self-report 30-34 21,200
35-39 21,000
40-44 21,600
45-49 23,400
50-54 26,200
55-59 27,700
60-64 29,700
65-69 32,800
70-74 37,300
75-79 42,600
80-84 48,600
≥85 54,600

Race

  • Constipation usually affects individuals of the non-Caucasian race. Caucasian individuals are less likely to develop constipation.
  • The non-White to White ratio of involving in constipation is from 1.13 to 2.89 (Mean 1.68, Median 1.41).[4][8]

Gender

  • Females are more commonly affected by constipation than males. The female to male ratio is approximately 2.2 to 1.[4]
  • Female to male ratio suffering from constipation in various studies is as the following:
Author Criteria Male Female Female to male ratio
Sandler[9] Self-report 7 18.2 2.6
Johnson[10] Self-report 0.9 2.8 3.11
Pare[11] Self-report 18.4 35.4 1.92
ROME I 12 21 1.75
ROME II 8.3 21.1 2.54
Talley[12] Self-report 2.7 7.3 2.7
ROME I functional constipation (FC) 18.3 20.1 1.01
ROME I outlet obstruction (OD) 5.2 16.5 3.17

Region

  • There is no regional difference in the prevalence of constipation.

Developed and Developing Countries

  • Developing countries with lower income show higher prevalence of constipation rather than developed countries with higher income.
  • Educational years in the population show an inverse relationship with prevalence of constipation.
Author Criteria Income Education
USD per year Prevalence

(per 100,000 individuals)

Status Prevalence

(per 100,000 individuals)

Sandler[9] Self-report < 7,000 18,600 0-6 years 21,700
7,000-9,999 13,300 7-11 years 15,300
10,000-14,999 11,600 12 years 12,200
≥ 15,000 8,600 More than 13 years 11,200
Johnson[10] Self-report 0-9,999 3,690
10,000-19,999 2,290
20,000-34,999 1,470
≥ 35,000 1,080
Pare[11] Self-report <20,000 33,800 Grade school 28,700
20,000-39,999 23,700 Some high school 35,100
High school 24,600
40,000-59,999 24,300 High school diploma 29,400
Technician school 20,500
60,000-79,999 28,000 Some College 25,400
College 31,500
≥ 80,000 21,800 Graduate school 19,600
ROME I functional constipation (FC) <20,000 18,500 Grade school 14,300
20,000-39,999 16,300 Some high school 23,800
High school 18,800
40,000-59,999 17,600 High school diploma 22,100
Technician school 15,000
60,000-79,999 13,100 Some College 9,900
College 17,200
≥ 80,000 12,100 Graduate school 11,300
ROME II <20,000 15,300 Grade school 4,300
20,000-39,999 14,300 Some high school 21,700
High school 18,600
40,000-59,999 13,900 High school diploma 18,400
Technician school 12,000
60,000-79,999 14,500 Some College 8,600
College 16,500
≥ 80,000 8,300 Graduate school 10,000
Talley[12] ROME I functional constipation (FC) Less than high school graduated 23,300
High school graduated 18,400
More than high school graduated 18,000
ROME I outlet obstruction (OD) Less than high school graduated 16,300
High school graduated 8,700
More than high school graduated 12,000

References

  1. Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ (2007). “Cumulative incidence of chronic constipation: a population-based study 1988-2003”. Aliment. Pharmacol. Ther. 26 (11–12): 1521–8. doi:10.1111/j.1365-2036.2007.03540.x. PMID 17919271.
  2. Johanson JF, Sonnenberg A, Koch TR (1989). “Clinical epidemiology of chronic constipation”. J. Clin. Gastroenterol. 11 (5): 525–36. PMID 2551954.
  3. Stewart WF, Liberman JN, Sandler RS, Woods MS, Stemhagen A, Chee E, Lipton RB, Farup CE (1999). “Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features”. Am. J. Gastroenterol. 94 (12): 3530–40. doi:10.1111/j.1572-0241.1999.01642.x. PMID 10606315.
  4. 4.0 4.1 4.2 Higgins PD, Johanson JF (2004). “Epidemiology of constipation in North America: a systematic review”. Am. J. Gastroenterol. 99 (4): 750–9. doi:10.1111/j.1572-0241.2004.04114.x. PMID 15089911.
  5. Koloski NA, Jones M, Wai R, Gill RS, Byles J, Talley NJ (2013). “Impact of persistent constipation on health-related quality of life and mortality in older community-dwelling women”. Am. J. Gastroenterol. 108 (7): 1152–8. doi:10.1038/ajg.2013.137. PMID 23670115.
  6. Chang JY, Locke GR, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, Talley NJ (2010). “Impact of functional gastrointestinal disorders on survival in the community”. Am. J. Gastroenterol. 105 (4): 822–32. doi:10.1038/ajg.2010.40. PMC 2887253. PMID 20160713.
  7. HAMMOND EC (1964). “SOME PRELIMINARY FINDINGS ON PHYSICAL COMPLAINTS FROM A PROSPECTIVE STUDY OF 1,064,004 MEN AND WOMEN”. Am J Public Health Nations Health. 54: 11–23. PMC 1254627. PMID 14117648.
  8. Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP, White LR (1989). “A longitudinal survey of self-reported bowel habits in the United States”. Dig. Dis. Sci. 34 (8): 1153–62. PMID 2787735.
  9. 9.0 9.1 Sandler RS, Jordan MC, Shelton BJ (1990). “Demographic and dietary determinants of constipation in the US population”. Am J Public Health. 80 (2): 185–9. PMC 1404600. PMID 2297063.
  10. 10.0 10.1 Johanson JF (1998). “Geographic distribution of constipation in the United States”. Am. J. Gastroenterol. 93 (2): 188–91. doi:10.1111/j.1572-0241.1998.00188.x. PMID 9468239.
  11. 11.0 11.1 Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L (2001). “An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking”. Am. J. Gastroenterol. 96 (11): 3130–7. doi:10.1111/j.1572-0241.2001.05259.x. PMID 11721760.
  12. 12.0 12.1 Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ (1993). “Functional constipation and outlet delay: a population-based study”. Gastroenterology. 105 (3): 781–90. PMID 8359649.

Template:WikiDoc Sources

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

The most potent risk factor in the development of constipation is inappropriate diet. Common risk factors include female gender, > 65 years of age, pregnancy, and iron supplements.

Risk Factors

  • The most potent risk factor in the development of constipation is inappropriate diet. Other risk factors include female gender, > 65 years of age, pregnancy, and iron supplements.

Common Risk Factors

Less Common Risk Factors

References

  1. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L (2001). “An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking”. Am. J. Gastroenterol. 96 (11): 3130–7. doi:10.1111/j.1572-0241.2001.05259.x. PMID 11721760.
  2. Talley NJ, Jones M, Nuyts G, Dubois D (2003). “Risk factors for chronic constipation based on a general practice sample”. Am. J. Gastroenterol. 98 (5): 1107–11. doi:10.1111/j.1572-0241.2003.07465.x. PMID 12809835.
  3. 3.0 3.1 Sandler RS, Jordan MC, Shelton BJ (1990). “Demographic and dietary determinants of constipation in the US population”. Am J Public Health. 80 (2): 185–9. PMC 1404600. PMID 2297063.
  4. 4.0 4.1 Johanson JF, Sonnenberg A, Koch TR (1989). “Clinical epidemiology of chronic constipation”. J. Clin. Gastroenterol. 11 (5): 525–36. PMID 2551954.
  5. 5.0 5.1 Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP, White LR (1989). “A longitudinal survey of self-reported bowel habits in the United States”. Dig. Dis. Sci. 34 (8): 1153–62. PMID 2787735.

Template:WH Template:WS

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

According to the USPSTF, screening for constipation is not recommended in general population. In palliative care patients, screening for constipation by specific questionnaire about subjective and objective findings is recommended.

Screening

  • According to the USPSTF, screening for constipation is not recommended in general population.
Group Question Answer interpretation
Symptoms Do you have pain, discomfort or a sensation of incomplete evacuation when having a bowel movement? Positive response reflects constipation
Please indicate the degree of ‘‘discomfort or difficult with constipation’’

0=None

10=Maximum discomfort

Higher scores reflect more constipation severity
Signs On average: How many bowel movements per week do you estimate you have had over the last 3 weeks? < 3 movements reflects constipation
Please indicate the usual hardness of your bowels.

Hard, soft or normal?

Are they runny or pasty?

Hard consistency reflects constipation
Fecal impaction Fecal impaction defined as the accumulation of hard feces in the rectum that would require unusual effort to evacuate, such as manual extraction, repetitive enemas, or intensive oral use of laxatives. Positive response reflects constipation

References

  1. 1.0 1.1 Noguera A, Centeno C, Librada S, Nabal M (2009). “Screening for constipation in palliative care patients”. J Palliat Med. 12 (10): 915–20. doi:10.1089/jpm.2009.0054. PMID 19747036.

Template:WS Template:WH

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

The symptoms of constipation can develop in the different decades of life, and starts with symptoms such as bloating, mucus passage, and abdominal pain. Then the symptoms increase in severity by hardening of stool which is contributes to straining and inability to pass the stool, may be need for manual evacuation. Common complications of chronic constipation include hemorrhoid, anal fissure, fecal impaction, and rectal prolapse. The colonic transit time (CTT) more than 100 hours is associated with a particularly poor prognosis among patients with constipation.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

  • Prognosis is generally excellent, and the survival rate of patients with constipation is approximately 100%.
  • The presence of palpable rectal mass and female gender is associated with a good prognosis among patients with constipation.[3]
  • The colonic transit time (CTT) more than 100 hours is associated with a particularly poor prognosis among patients with constipation.[4][5][6]

References

  1. Choung RS, Locke GR, Rey E, Schleck CD, Baum C, Zinsmeister AR; et al. (2012). “Factors associated with persistent and nonpersistent chronic constipation, over 20 years”. Clin Gastroenterol Hepatol. 10 (5): 494–500. doi:10.1016/j.cgh.2011.12.041. PMC 3589972. PMID 22289877.
  2. Cheng M, Ghahremani S, Roth A, Chawla SC (2016). “Chronic Constipation and Its Complications: An Interesting Finding to an Otherwise Commonplace Problem”. Glob Pediatr Health. 3: 2333794X16648843. doi:10.1177/2333794X16648843. PMC 4905124. PMID 27336021.
  3. de Lorijn F, van Wijk MP, Reitsma JB, van Ginkel R, Taminiau JA, Benninga MA (2004). “Prognosis of constipation: clinical factors and colonic transit time”. Arch Dis Child. 89 (8): 723–7. doi:10.1136/adc.2003.040220. PMC 1720034. PMID 15269069.
  4. Benninga MA, Büller HA, Tytgat GN, Akkermans LM, Bossuyt PM, Taminiau JA (1996). “Colonic transit time in constipated children: does pediatric slow-transit constipation exist?”. J. Pediatr. Gastroenterol. Nutr. 23 (3): 241–51. PMID 8890073.
  5. Verduron A, Devroede G, Bouchoucha M, Arhan P, Schang JC, Poisson J, Hémond M, Hébert M (1988). “Megarectum”. Dig. Dis. Sci. 33 (9): 1164–74. PMID 3409803.
  6. Benninga MA, Büller HA, Heymans HS, Tytgat GN, Taminiau JA (1994). “Is encopresis always the result of constipation?”. Arch. Dis. Child. 71 (3): 186–93. PMC 1029969. PMID 7979489.

Template:WH Template:WS

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Abdominal X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Template:Gastroenterology

Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH